Printer Friendly

Expedited partner treatment said to merit wider application.

MONTREAL--Expedited partner treatment, also known as patient-delivered partner therapy, could substantially reduce costs and morbidity from sexually transmitted diseases if it were allowed in all states, according to Dr. Margaret Villers.

The practice allows physicians who are treating patients with sexually transmitted diseases to either provide treatment or write a prescription for their patients' partners without requiring the partners to come in to the office.

Although the Centers for Disease Control and Prevention has encouraged expedited partner treatment (EPT) since 2006, it is explicitly legal in only 19 states, and "in multiple states and localities, there are legal barriers which may prevent universal implementation," Dr. Villers said at the annual meeting of the Infectious Diseases Society for Obstetrics and Gynecology (For a map showing the legal status of EPT in each state, visit www.cdc.gov/std/ept/legal/default.htm.)

"The South Carolina statute very much mirrors the other states where it's prohibited in the sense that if you do not see a patient--if you've never met them, if you have not examined them, and if you do not have an ongoing relationship with them--then you are not allowed to prescribe a medication for them," explained Dr. Villers of the Medical University of South Carolina, Charleston.

In a cost-utility model examining the potential impact of EPT in 11 states where it was illegal in 2007 (one state, North Dakota, has since made the practice legal), she estimated there would be a cost savings of almost $6 million and the prevention of more than 2,000 cases of Chlamydia trachomatis and Neisseria gonorrhoeae annually.

The model suggested that EPT would have resulted in 984 fewer cases of chlamydia (out of the actual 196,819 cases) and 1,280 fewer cases of gonorrhea (out of the actual 56,585 cases). This would have resulted in a net savings of $1,671, 387 for chlamydia and $4, 163,534 for gonorrhea, and a combined gain of 453 quality-adjusted life years, she said.

In the 19 U.S. states where EPT is explicitly legal, "there are state statutes that either allow for the provision of a prescription in general or specifically for the treatment of STDs only," she said. But the laws are "somewhat murky" in 21 states.

She said that approximately 1 year ago the American Bar Association sent an open letter to all members encouraging states and localities to pass statutes that might decrease barriers to EPT.

"Improved clarification of the legal status of EPT, whether it is a state law which only allows the prescription of medications for STDs or whether it is a broader general law, might actually make this type of treatment more acceptable to physicians," she said in an interview Dr. Villers noted that her study probably underestimates the benefits of EPT by assuming that the infected patient is female, and by considering only the 3-month period following her treatment. In addition, "we did not take into account multiple sexual partners, and we also only looked at direct medical costs."
COPYRIGHT 2009 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:INFECTIOUS DISEASES
Author:Johnson, Kate
Publication:Internal Medicine News
Article Type:Report
Geographic Code:1CANA
Date:Oct 1, 2009
Words:503
Previous Article:FDA panel supports HPV vaccine for boys and men.
Next Article:Short psychiatric screen useful in primary care.
Topics:


Related Articles
The Emerging Infectious Diseases journal: a time of transition. (Editorial).
Patient-delivered Tx for partners reduces gonorrhea, chlamydia rates.
Patient-delivered Tx for partners lowers rates of some STDs.
Expedited partner treatment for STIs.
Expedited partner Tx for STDs urged.
Expedited partner treatment merits expansion.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |